GalenLogic is “Pharmaceutical Intelligence” software for the pharmaceutical industry. Its main products include Aura PV and Aura STP. Aura PV focuses on AI-powered pharmacovigilance, aiming to compress the workflow from adverse event report intake to FDA submission readiness down to seconds. Aura STP is designed for ACA Section 6004 drug sample transparency reporting, emphasizing that the process from spreadsheet to FDA submission can be completed within two minutes.
On the AI side, the official website says it uses machine learning to automatically process adverse event reports. It can extract medical terminology, perform MedDRA coding, identify duplicate cases, assess seriousness criteria, and generate submission-ready forms for FDA MedWatch and VAERS systems. For sample transparency, Aura STP automates data transformation and submission workflows. Overall, this is not a general-purpose AI assistant, but a vertical tool embedded into pharmacovigilance and regulatory submission workflows.
Pricing information is limited. The terms of service only state that access to product features is governed by separate subscription agreements; no public plans, free trial, or free tier are disclosed. Compliance is a key selling point: Aura says it is designed for HIPAA-regulated environments, with administrative, physical, and technical safeguards, and is designed to meet 21 CFR Part 11 requirements for electronic records and electronic signatures. However, the website does not disclose deployment options, data residency, audit details, or security certifications.
Its strengths are its highly specific use case, coverage of high-value pharmacovigilance workflows for pharmaceutical companies, and targeted support for U.S. regulatory scenarios such as FDA MedWatch, VAERS, and ACA Section 6004. The limitations are also clear: it does not disclose model sources, accuracy, validation data, or human review mechanisms. The terms of service explicitly state that users remain responsible for verifying the accuracy and completeness of regulatory submissions, and that regulatory acceptance is not guaranteed. There is also no visible information about APIs, enterprise system integrations, or Chinese-language support.
It is best suited for pharmaceutical companies, biotech firms, and CROs working under U.S. FDA compliance requirements, especially teams dealing with large volumes of individual adverse event cases or drug sample reporting obligations. For Chinese users, the website does not provide information on network accessibility from China, RMB payments, a Chinese interface, or adaptation to Chinese drug regulatory requirements, so access status should be considered unknown. If it is to be used for domestic pharmacovigilance workflows in China, teams still need to evaluate regulatory mapping, cross-border data transfer, and local alternatives.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on galenlogic.com official site.
galenlogic.com is an United States AI Apps provider. TG4G tracks its product information, an overall rating of 7.0/10, and a China-accessibility score of Workable. Click "Visit Official Site" to reach galenlogic.com directly.